All In Biotech

Drug Trial Radar · NCT04798209

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects

A Single-center, Double-blind, Randomized, Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jun 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

70

Actual

Start

Jan 29, 2021

Primary completion

Jan 26, 2022

Study completion May 21, 2022

Sponsor

Lead sponsor
Idorsia Pharmaceuticals Ltd.Industry
Sponsor type
Industry
First posted
Mar 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A study to examine the safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of ACT-777991 in healthy subjects.

Conditions

  • Healthy

Interventions

  • ACT-777991 (SAD)Drug

    ACT-777991 administered as hard capsules for oral use.

  • ACT-777991 (MAD)Drug

    ACT-777991 administered as hard capsules for oral use, once daily.

  • Placebo (SAD)Drug

    ACT-777991 matching placebo administered as hard capsules for oral use.

  • Placebo (MAD)Drug

    Matching placebo administered as hard capsules for oral use, once daily.

  • 14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)Drug

    Single dose of 14C-ACT-777991 microtracer, administered intravenously.

  • Microtracer matching placebo (SAD - Absolute Bioavailability)Drug

    Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.

  • 14C-ACT-777991 microtracer (MAD - ADME)Drug

    Single dose of 14C-ACT-777991 microtracer, oral solution..

  • Microtracer matching placebo (MAD - ADME)Drug

    Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events.Time frame: From first dose on Day 1 to Day 4 after the last dose was administered

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • QPS Netherlands B.V.

    Groningen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.